Application of the "Off-Clamp And Sutureless" Technique in Robot-Assisted Partial Nephrectomy
1 other identifier
interventional
190
1 country
1
Brief Summary
The detection rate of renal masses smaller than 7 cm has significantly increased in recent years. To preserve postoperative renal function to the greatest extent possible, guidelines from the European Association of Urology (EAU), the National Comprehensive Cancer Network (NCCN), and others have endorsed partial nephrectomy (PN) as the preferred treatment strategy for small renal masses. In conventional PN, it is necessary to clamp the renal artery or its branch arteries and employ a double-layer suturing technique to close the resection bed. This controls bleeding, maintains a clear surgical field, and prevents postoperative urinary leakage. The maximum safe duration of warm ischemia to avoid irreversible renal parenchymal damage remains controversial, though most studies indicate a window of 20-30 minutes. Consequently, the "off-clamp sutureless" concept has gained prominence. Its core principle is to avoid renal artery clamping and replace suturing with novel haemostatic techniques, thereby maximizing the preservation of healthy renal parenchyma. With the diversification of haemostatic material options and the widespread adoption of robotic-assisted systems, the off-clamp sutureless strategy has become technically feasible for small renal masses with low complexity . Multiple retrospective studies demonstrate that the off-clamp sutureless technique is non-inferior, offering safety and surgical outcomes comparable to conventional robot-assisted partial nephrectomy (RAPN). However, it is important to note that current research predominantly focuses on tumors ≤4 cm, is largely retrospective, and suffers from limited sample sizes. More robust, evidence-based medical evidence is required to support its application for larger tumors or those with complex anatomy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2025
CompletedFirst Submitted
Initial submission to the registry
August 19, 2025
CompletedFirst Posted
Study publicly available on registry
August 26, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2028
September 5, 2025
August 1, 2025
2 years
August 19, 2025
August 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Bilateral Kidney GFR
Measured by 99mTc-DTPA
3 months after surgery
Secondary Outcomes (2)
Perioperative Complication Rate
1 week after surgery
Intraoperative Blood Loss
during surgery
Study Arms (1)
Off-Clamp Sutureless Group
EXPERIMENTALInterventions
During the procedure, the renal artery and its branches are not clamped. The tumor is completely resected with a gross margin of 0.5-1 cm from its edge. Monopolar or bipolar electrocautery is used for hemostasis during resection. Following tumor removal, the renal resection bed is subjected to meticulous hemostasis, followed by the application of hemostatic agents without suture closure.
Eligibility Criteria
You may qualify if:
- Age between 18 and 80 years old, regardless of gender;
- Radiological findings demonstrating a tumor size of ≤7 cm;
- Imaging studies showing no evidence of collecting system invasion;
- Scheduled to undergo robot-assisted partial nephrectomy (RAPN).
You may not qualify if:
- Preoperative imaging demonstrating evidence of distant metastasis or lymph node involvement;
- Unilateral or bilateral multiple lesions not amenable to simultaneous resection;
- History of prior systemic therapy, including molecular targeted therapy, immunotherapy, or chemotherapy;
- Intraoperative conversion to radical nephrectomy;
- Intraoperative conversion to open surgery.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Shao Pengfeilead
Study Sites (1)
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
Nanjing, Jiangsu, 210036, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pengfei Shao, Professor
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), Nanjing, Jiangsu 210036
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 19, 2025
First Posted
August 26, 2025
Study Start
June 1, 2025
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 30, 2028
Last Updated
September 5, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share
Without obtaining prior consent from the participant.